New Diagnostic and Therapeutic Strategies for Pulmonary Hypertension Associated with Left Heart Disease

[1]  S. Rosenkranz,et al.  Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1) , 2014, Chest.

[2]  J. Huffmyer,et al.  Effects of early inhaled epoprostenol therapy on pulmonary artery pressure and blood loss during LVAD placement. , 2014, Journal of cardiothoracic and vascular anesthesia.

[3]  F. Martinez,et al.  Pulmonary hypertension due to left heart diseases. , 2013, Journal of the American College of Cardiology.

[4]  B. Borlaug,et al.  Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. , 2013, JACC. Heart failure.

[5]  S. Rosenkranz,et al.  Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE-1): A randomized, double-blind, placebo-controlled, single-dose study , 2013 .

[6]  H. Ghofrani,et al.  Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction: A Phase IIb Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Hemodynamic Study , 2013, Circulation.

[7]  W. Abraham.  Disease management: remote monitoring in heart failure patients with implantable defibrillators, resynchronization devices, and haemodynamic monitors. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[8]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[9]  M. Humbert,et al.  Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[10]  R. Naeije,et al.  The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease , 2012, European Respiratory Journal.

[11]  V. Roger,et al.  Pulmonary pressures and death in heart failure: a community study. , 2012, Journal of the American College of Cardiology.

[12]  M. Borggrefe,et al.  Intrathoracic Impedance Monitoring, Audible Patient Alerts, and Outcome in Patients With Heart Failure , 2011, Circulation.

[13]  R. Hetzer,et al.  Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients. , 2011, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[14]  J. Cleveland,et al.  Survival after biventricular assist device implantation: an analysis of the Interagency Registry for Mechanically Assisted Circulatory Support database. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[15]  M. Enriquez-Sarano,et al.  Prognostic and therapeutic implications of pulmonary hypertension complicating degenerative mitral regurgitation due to flail leaflet: a multicenter long-term international study. , 2011, European heart journal.

[16]  L. Stevenson,et al.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.

[17]  R. Arena,et al.  PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study , 2011, Circulation. Heart failure.

[18]  N. Voelkel,et al.  Reversible or irreversible remodeling in pulmonary arterial hypertension. , 2010, American journal of respiratory cell and molecular biology.

[19]  M. Chakinala,et al.  Modulating the nitric oxide – cyclic GMP pathway in the pressure‐overloaded left ventricle and group II pulmonary hypertension , 2010, International journal of clinical practice. Supplement.

[20]  W. Manning,et al.  Pulmonary hypertension and long-term mortality in aortic and mitral regurgitation. , 2010, American Journal of Medicine.

[21]  M. Raizada,et al.  The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. , 2010, American journal of respiratory and critical care medicine.

[22]  Young H. Lee,et al.  Angiotensin-II-induced apoptosis requires regulation of nucleolin and Bcl-xL by SHP-2 in primary lung endothelial cells , 2010, Journal of Cell Science.

[23]  J. Newman,et al.  Association of the metabolic syndrome with pulmonary venous hypertension. , 2009, Chest.

[24]  Horst Olschewski,et al.  Diagnosis and assessment of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[25]  W. Kraus,et al.  Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. , 2009, JAMA.

[26]  D. Yuh,et al.  PDE5A Inhibitor Treatment of Persistent Pulmonary Hypertension After Mechanical Circulatory Support , 2008, Circulation. Heart failure.

[27]  Pascal Leprince,et al.  Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock* , 2008, Critical care medicine.

[28]  C. O'connor,et al.  Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. , 2007, JAMA.

[29]  R. Gerszten,et al.  Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension , 2007 .

[30]  M. Metra,et al.  Optimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[31]  F. López-Ríos,et al.  Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure , 2005, European journal of heart failure.

[32]  T. Mesana,et al.  Left Ventricular Assist Devices as Bridge to Heart Transplantation in Congestive Heart Failure with Pulmonary Hypertension , 2005, ASAIO journal.

[33]  W. Zapol,et al.  Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. , 2005, Chest.

[34]  D. DeMets,et al.  Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. , 2005, Journal of cardiac failure.

[35]  M. Lachat,et al.  Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates. , 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[36]  J. McMurray,et al.  Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin-A Receptor Antagonist Trial in heart failure (EARTH): Randomised, double-blind, placebo-controlled trial , 2004 .

[37]  J. McMurray,et al.  Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[38]  I. Piña,et al.  Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. , 2003, Circulation.

[39]  F. Beyersdorf,et al.  Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation-a preliminary study. , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[40]  A. Coats,et al.  Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? , 2002, International journal of cardiology.

[41]  W. Colucci,et al.  Endothelin Mediates Increased Pulmonary Vascular Tone in Patients With Heart Failure: Demonstration by Direct Intrapulmonary Infusion of Sitaxsentan , 2002, Circulation.

[42]  M. Maclean,et al.  Pulmonary hypertension secondary to left ventricular dysfunction: the role of nitric oxide and endothelin‐1 in the control of pulmonary vascular tone , 2002, British journal of pharmacology.

[43]  W. Colucci,et al.  Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. , 2000, Circulation.

[44]  J. Young,et al.  Outpatient parenteral inotropic therapy for advanced heart failure. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[45]  V. Bittner,et al.  Assessing Functional Capacity as an Outcome in Cardiac Rehabilitation , 2000 .

[46]  C. Opitz,et al.  Acetylcholine but not sodium nitroprusside exerts vasodilation in pulmonary hypertension secondary to chronic congestive heart failure. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[47]  A. Selwyn,et al.  The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. , 1998, The American journal of cardiology.

[48]  F. Harrell,et al.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). , 1997, American heart journal.

[49]  N. Morrell,et al.  Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. , 1995, The American journal of physiology.

[50]  R. Kacmarek,et al.  Hemodynamic effects of inhaled nitric oxide in heart failure. , 1994, Journal of the American College of Cardiology.

[51]  Y. Sugishita,et al.  Endothelin receptor subtypes in human versus rabbit pulmonary arteries. , 1994, Journal of applied physiology.

[52]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[53]  E. Blackstone,et al.  Pulmonary vascular resistance and the risk of heart transplantation. , 1988, The Journal of heart transplantation.

[54]  N. Fukunaga,et al.  The impact of preoperative and postoperative pulmonary hypertension on long-term surgical outcome after mitral valve repair for degenerative mitral regurgitation. , 2015, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[55]  M. Gatzoulis,et al.  [Updated clinical classification of pulmonary hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[56]  R. Arena,et al.  PDE 5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function , Cardiac Geometry , and Clinical Status in Patients With Stable Systolic Heart Failure , 2011 .

[57]  D. Yuh,et al.  A Inhibitor Treatment of Persistent Pulmonary Hypertension After Mechanical Circulatory Support , 2008 .

[58]  L. Tavazzi,et al.  Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. , 2001, Journal of the American College of Cardiology.

[59]  A Costard-Jäckle,et al.  Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. , 1992, Journal of the American College of Cardiology.